£84.32

Springer Radiation Oncology Advances: 139 (Cancer Treatment and Research, 139)

Refer to Sapnet.

Price data checked 1 day ago

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

About as cheap as it gets. The only time it was cheaper was 3 months ago.

£84 today · all-time low £82 (Apr 2026) · usually £84

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 90 days • 90 data points

Historical
Generating forecast...
£84.86 £81.77 £82.44 £83.12 £83.79 £84.47 £85.14 05 April 2026 27 April 2026 19 May 2026 10 June 2026 03 July 2026

Price Distribution

Price distribution over 90 days • 4 price levels

Days at Price
Current Price
19 days 24 days 33 days · current 14 days 0 8 17 25 33 £82 £83 £84 £85 Days at Price

Price Analysis

Most common price: £84 (33 days, 36.7%)

Price range: £82 - £85

Price levels: 4 different prices over 90 days

Description

from combining radiation with a molecular targeted agent – namely cetuximab, a recombinant mouse/human chimeric monoclonal antibody against the Epidermal Growth Factor (EGF) receptor [4] Astsaturov, Cohen and Harari present a more indepth review of the biology of the EGF Receptor and its signaling pathway in Chap. 7 as a potential target in combination with fractionated radiotherap y for head and neck squamous cell carcinoma (HNSCC). A flurry of agents are under de velopment for targeting EGFR and in March 2006, the US Food and Drugs Administration approved cetuximab combined with radiation as a primary treatment option for patients with loco-regionally advanced HNSCC in whom chemoradiation therapy is deemed not to be an option. While blocking the EGF pathway during fractionated radiotherapy may seem an obvious strategy [5], the rationale for combining antiangiogenic and antivascular targeting agents with radiation may be less intuitive. However, recent research shows that there are several reasons why this could result in a therapeutic gain in practice. Chapter 8 is a review of this rapidly expanding field by Citrin and Camphausen. Targeted agents combined with radiation may offer new opportunities in the treatment of central nervous system malignancies, a tumor type where the outlook remains poor despite some recent progress [6]. Current attempts to overcome rad- tion resistance in these tumors on the basis of an improved understanding of their molecular biology are the topic of Chap. 9 by Chakravarti and Palanichamy.

Product Specifications

Barcode

No barcode data available

Similar Products You Might Like

Radiation Oncology Advances: 139 (Cancer Treatment and Research, 139)
100% match

Radiation Oncology Advances: 139 (Cancer Treatment and Research, 139)

Springer

£80.66 04 Jul 2026
Modification of Radiation Response: Cytokines, Growth Factors and Other Biological Targets (Medical Radiology / Diagnostic Imaging)
81% match

Modification of Radiation Response: Cytokines, Growth Factors and Other Biological Targets (Medical Radiology / Diagnostic Imaging)

Springer

£53.53 16 May 2026
Increasing the Therapeutic Ratio of Radiotherapy (Cancer Drug Discovery and Development)
80% match

Increasing the Therapeutic Ratio of Radiotherapy (Cancer Drug Discovery and Development)

Humana

£104.85 29 May 2026
Systemic Radiotherapy with Monoclonal Antibodies: Options and Problems: 141 (Recent Results in Cancer Research, 141)
80% match

Systemic Radiotherapy with Monoclonal Antibodies: Options and Problems: 141 (Recent Results in Cancer Research, 141)

Springer

£77.58 03 Jun 2026
Radiation Therapy for Head and Neck Cancers: A Case-Based Review
80% match

Radiation Therapy for Head and Neck Cancers: A Case-Based Review

Springer

£68.90 17 May 2026
Head and Neck Cancer: 114 (Cancer Treatment and Research, 114)
79% match

Head and Neck Cancer: 114 (Cancer Treatment and Research, 114)

Springer

£113.94 01 Jun 2026
Radiotherapy in Managing Brain Metastases: A Case-Based Approach
79% match

Radiotherapy in Managing Brain Metastases: A Case-Based Approach

Springer

£73.10 05 Jun 2026
Targeted Radionuclide Tumor Therapy: Biological Aspects
78% match

Targeted Radionuclide Tumor Therapy: Biological Aspects

Springer

£130.93 20 May 2026
Head and Neck Oncology: 22 (Cancer Treatment and Research, 22)
78% match

Head and Neck Oncology: 22 (Cancer Treatment and Research, 22)

Springer

£149.64 25 May 2026
Gynecologic Radiation Therapy: Novel Approaches to Image-Guidance and Management
78% match

Gynecologic Radiation Therapy: Novel Approaches to Image-Guidance and Management

Springer

£88.17 05 Jun 2026
Thermoradiotherapy and Thermochemotherapy: Biology, Physiology, Physics (Medical Radiology)
78% match

Thermoradiotherapy and Thermochemotherapy: Biology, Physiology, Physics (Medical Radiology)

Springer

£176.18 24 Jun 2026
Chemotherapy and Radiotherapy of Gastrointestinal Tumors: 79 (Recent Results in Cancer Research, 79)
78% match

Chemotherapy and Radiotherapy of Gastrointestinal Tumors: 79 (Recent Results in Cancer Research, 79)

Springer

£77.42 03 Jul 2026
Oncology of CNS Tumors
78% match

Oncology of CNS Tumors

Springer

£179.99 26 May 2026
Tumors of the Central Nervous system, Volume 3: Brain Tumors (Part 1)
78% match

Tumors of the Central Nervous system, Volume 3: Brain Tumors (Part 1)

Springer

£11.80 01 Jun 2026
Non-Small Cell Lung Cancer: New Research (Cancer Etiology, Diagnosis and Treatments)
78% match

Non-Small Cell Lung Cancer: New Research (Cancer Etiology, Diagnosis and Treatments)

£65.39 26 May 2026
Radiation Treatment and Radiation Reactions in Dermatology
78% match

Radiation Treatment and Radiation Reactions in Dermatology

Springer

£109.99 06 Jun 2026
Soft Tissue Sarcomas: Present Achievements and Future Prospects: 91 (Cancer Treatment and Research, 91)
78% match

Soft Tissue Sarcomas: Present Achievements and Future Prospects: 91 (Cancer Treatment and Research, 91)

Springer

£163.78 13 Jun 2026
Brain Tumor Immunotherapy
77% match

Brain Tumor Immunotherapy

Humana

£129.72 03 Jun 2026
Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models
77% match

Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models

Springer

£74.57 05 Jun 2026
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy (Imaging in Medical Diagnosis and Therapy)
77% match

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy (Imaging in Medical Diagnosis and Therapy)

CRC Press

£73.44 01 Jul 2026
Functional Preservation and Quality of Life in Head and Neck Radiotherapy (Medical Radiology)
77% match

Functional Preservation and Quality of Life in Head and Neck Radiotherapy (Medical Radiology)

Springer

£102.67 30 Jun 2026
Radiation Therapy for Pelvic Malignancy and its Consequences
77% match

Radiation Therapy for Pelvic Malignancy and its Consequences

Springer

£66.80 18 May 2026
Robotic Radiosurgery. Treating Tumors that Move with Respiration
77% match

Robotic Radiosurgery. Treating Tumors that Move with Respiration

Springer

£81.58 28 May 2026
Soft Tissue Sarcomas: New Developments in the Multidisciplinary Approach to Treatment: 56 (Cancer Treatment and Research, 56)
77% match

Soft Tissue Sarcomas: New Developments in the Multidisciplinary Approach to Treatment: 56 (Cancer Treatment and Research, 56)

Springer

£148.53 26 May 2026